Algunos estudios en modelos animales han mostrado que el bloqueo de su receptor protege contra la obesidad, mientras que otros han evidenciado que los agonistas de GIPR, especialmente en combinacin con GLP-1RA, inducen una prdida de peso superior y reducen la intolerancia al tratamiento asociada con nuseas
Introduction Functional Dyspepsia Functional dyspepsia (FD), defined as epigastric symptoms affecting daily life, such as postprandial fullness, early satiation, epigastric pain and burning, in the absence of underlying organic abnormalities ( H
showed in atherosclerosis-prone apolipoprotein E-deficient (ApoE / ) and insulin-resistant mice that lixisenatide can diminish the atherosclerosis burden by reducing the size of atheroma plaques, increasing plaque stability, and reprogramming macrophages to the anti-inflammatory M2 phenotype by enhanced activation of signal transducer and activator of transcription (STAT)3, which is a determinant for M2 macrophage differentiation
Glucagon activation increases energy expenditure and fat oxidation, adding a calorie-burning mechanism on top of the appetite suppression delivered by GLP-1 and GIP agonism
Waiting less than 30 minutes reduces this advantage
[2] Mosca L, Minopoli M, Pagano M, Vitiello F, Carriero MV, Cacciapuoti G, Porcelli M
